“…We found that early ST was associated with significantly higher inhospital and 30-day mortality, in keeping with the findings of previously published studies [18,19] found to be a predictor of ST, which was not the case in our study. The significant increase in the rate of minor bleeding in the early ST could be explained by the higher and longer use of anticoagulation post repeat revascularization.…”
Section: Discussionsupporting
confidence: 93%
“…We found that early ST was associated with significantly higher in‐hospital and 30‐day mortality, in keeping with the findings of previously published studies . Among the patients suffering early ST, mortality occurred in the ones who suffered ST after 24 hr.…”
Section: Discussionsupporting
confidence: 92%
“…matched patients in the two groups to assess the angiographic predictors of early ST. We found that the average stent diameter was significantly different in two groups, a finding consistent with a previous study [19]. We also noticed that patients with early ST had lower use of the intracoronary glycoprotein IIb/IIIa inhibitors.…”
The incidence of early ST in primary PCI cohort is low. However, it is still associated with higher mortality and morbidity. Small stent diameter and disuse of intracoronary glycoprotein IIb/IIIa inhibitor may be associated with early ST.
“…We found that early ST was associated with significantly higher inhospital and 30-day mortality, in keeping with the findings of previously published studies [18,19] found to be a predictor of ST, which was not the case in our study. The significant increase in the rate of minor bleeding in the early ST could be explained by the higher and longer use of anticoagulation post repeat revascularization.…”
Section: Discussionsupporting
confidence: 93%
“…We found that early ST was associated with significantly higher in‐hospital and 30‐day mortality, in keeping with the findings of previously published studies . Among the patients suffering early ST, mortality occurred in the ones who suffered ST after 24 hr.…”
Section: Discussionsupporting
confidence: 92%
“…matched patients in the two groups to assess the angiographic predictors of early ST. We found that the average stent diameter was significantly different in two groups, a finding consistent with a previous study [19]. We also noticed that patients with early ST had lower use of the intracoronary glycoprotein IIb/IIIa inhibitors.…”
The incidence of early ST in primary PCI cohort is low. However, it is still associated with higher mortality and morbidity. Small stent diameter and disuse of intracoronary glycoprotein IIb/IIIa inhibitor may be associated with early ST.
“…This is in contrast with analyses after percutaneous coronary angioplasty and stenting which had shown an inverse relationship between vessel size and recurrent ischemic events on follow-up 34. A longer lesion means greater plaque burden and increased probability of smooth muscle cell proliferation and migration to the neointima, which may be one of the underlying mechanisms leading to the recurrent events.…”
Stenting for VAO stenosis seems to be safe and efficacious. The majority of recurrent events were TIAs, which may be related to ISR, stent fracture, vessel tortuosity, and hyperlipidemia.
“…grel 75 mg/día+ácido acetil salicílico [AAS] 100 mg/día], la incidencia de trombosis en pacientes con un stent implantado continúa siendo del 0,5 al 3,3% de los casos[1][2][3][4][5] . En la mayoría de éstos la medicación se aplica de forma empírica, sin monitorizar el grado de efectividad antiplaquetaria del tratamiento, por lo que no suelen detectarse los pacientes noARTICLE IN PRESSCitometría de flujo para determinar microagregados plaquetarios…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.